Author:
Pavel M.E.,Baudin E.,Öberg K.E.,Hainsworth J.D.,Voi M.,Rouyrre N.,Peeters M.,Gross D.J.,Yao J.C.
Funder
Novartis Pharmaceuticals Corporation
Reference10 articles.
1. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States;Yao;J Clin Oncol,2008
2. National Comprehensive Cancer Network. Clinical practice guideline in oncology. Neuroendocrine tumors version 2. 2014; http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf (3 January 2017, last date accessed).
3. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study;Pavel;Lancet,2011
4. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment Of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000
5. Detecting an overall survival benefit that is derived from progression-free survival;Broglio;J Natl Cancer Inst,2009
Cited by
88 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献